Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACONWNASDAQ:BACKNASDAQ:BTTXNYSE:UPHL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACONWAclarion$0.03-2.7%$0.05$0.01▼$0.24N/AN/A52,508 shs18,522 shsBACKIMAC$0.04+19.8%$0.23$0.03▼$4.13$75K1.67439,357 shs34,061 shsBTTXBetter Therapeutics$0.00$0.00$0.00▼$0.03$10K1.1917,674 shs102,510 shsUPHLUpHealth$0.00$0.00$0.00▼$0.94$4K0.849,614 shs60 shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACONWAclarion-2.65%-15.17%-40.00%-36.05%-36.42%BACKIMAC+19.80%-9.25%-22.77%-94.16%-99.01%BTTXBetter Therapeutics0.00%0.00%-50.00%+100.00%-98.46%UPHLUpHealth0.00%0.00%0.00%0.00%-99.98%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACONWAclarionN/AN/AN/AN/AN/AN/AN/AN/ABACKIMACN/AN/AN/AN/AN/AN/AN/AN/ABTTXBetter TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AUPHLUpHealthN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACONWAclarion 0.00N/AN/AN/ABACKIMAC 0.00N/AN/AN/ABTTXBetter Therapeutics 0.00N/AN/AN/AUPHLUpHealth 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACONWAclarion$45.72KN/AN/AN/AN/AN/ABACKIMAC$72.05K1.04N/AN/A($0.66) per share-0.06BTTXBetter TherapeuticsN/AN/AN/AN/AN/AN/AUPHLUpHealth$130M0.00N/AN/A$3.10 per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACONWAclarionN/AN/A0.00∞N/AN/AN/AN/AN/ABACKIMAC-$9.42MN/A0.00∞N/AN/AN/A-325.44%5/5/2025 (Estimated)BTTXBetter Therapeutics-$39.76MN/A0.00∞N/AN/AN/AN/A5/5/2025 (Estimated)UPHLUpHealth-$56.42M-$1.35N/A∞N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACONWAclarionN/AN/AN/AN/AN/ABACKIMACN/AN/AN/AN/AN/ABTTXBetter TherapeuticsN/AN/AN/AN/AN/AUPHLUpHealthN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACONWAclarionN/AN/AN/ABACKIMACN/A0.080.08BTTXBetter TherapeuticsN/AN/AN/AUPHLUpHealthN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACONWAclarionN/ABACKIMAC5.84%BTTXBetter Therapeutics34.00%UPHLUpHealth56.10%Insider OwnershipCompanyInsider OwnershipACONWAclarionN/ABACKIMAC12.26%BTTXBetter Therapeutics51.40%UPHLUpHealth34.24%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACONWAclarion7N/AN/ANot OptionableBACKIMAC1802.07 million1.82 millionNot OptionableBTTXBetter Therapeutics4049.86 million24.23 millionOptionableUPHLUpHealth1,75018.93 million12.45 millionNo DataBACK, BTTX, UPHL, and ACONW HeadlinesRecent News About These CompaniesUpHealth, Inc. (UPHL) Latest Stock News & Headlines - Yahoo FinanceApril 24, 2025 | finance.yahoo.comLemon Dump Cake RecipeSeptember 9, 2024 | msn.comDJUSIV Dow Jones US Business Support Services IndexJuly 27, 2024 | seekingalpha.comUpHealth Inc Ordinary Shares UPHLJuly 19, 2024 | morningstar.comUpHealth Holdings, Inc. Wins Ruling in Calcutta High Court, Mandating All Glocal Healthcare Respondents Submit Affidavits of AssetsMay 24, 2024 | prnewswire.comUpHealth, Inc. (UPHL) Advances While Market Declines: Some Information for InvestorsApril 30, 2024 | zacks.comUpHealth, Inc. (UPHL)April 17, 2024 | finance.yahoo.comCalcutta High Court rules in favour of UpHealth Holdings, Inc., and vigorously reinforces the ICC International Court of Arbitration previous $110 million award against Glocal directors and other Respondents, calling their conduct “dishonest and fraudulent”April 16, 2024 | finance.yahoo.comUpHealth Holdings Takes Steps to Enforce the International Court of Arbitration’s Final Award to UpHealth Holdings of more than $110 Million in Damages in Breach of Contract Lawsuit Involving the 2020 Purchase by UpHealth of Glocal Healthcare SystemsApril 1, 2024 | finance.yahoo.comUpHealth, Inc.: UpHealth Provides Corporate Update and Announces Fourth Quarter and Full Year 2023 Financial ResultsMarch 22, 2024 | finanznachrichten.deUpHealth Provides Corporate Update and Announces Fourth Quarter and Full Year 2023 Financial ResultsMarch 21, 2024 | finance.yahoo.comHealthcare Triangle GAAP EPS of -$1.26, revenue of $7.1MMarch 18, 2024 | msn.comMedia Sentiment Over TimeTop HeadlinesView All HeadlinesAre Tariffs Threatening Disney’s Comeback Story?By Jea Yu | April 9, 2025View Are Tariffs Threatening Disney’s Comeback Story?These 3 Stocks Have Huge Last 12 Months Shareholder YieldsBy Leo Miller | April 18, 2025View These 3 Stocks Have Huge Last 12 Months Shareholder YieldsWho Led Buybacks to End 2024? Hint: It Wasn’t Big TechBy Leo Miller | April 8, 2025View Who Led Buybacks to End 2024? Hint: It Wasn’t Big TechTesla's Band-Aid Has Been Ripped Off: Rally Mode EngagedBy Sam Quirke | April 30, 2025View Tesla's Band-Aid Has Been Ripped Off: Rally Mode EngagedBest Defense Stocks in 2025... So FarBy Chris Markoch | April 28, 2025View Best Defense Stocks in 2025... So FarBACK, BTTX, UPHL, and ACONW Company DescriptionsAclarion NASDAQ:ACONW$0.03 0.00 (-2.65%) As of 05/2/2025 01:57 PM EasternAclarion, Inc., a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.IMAC NASDAQ:BACK$0.04 +0.01 (+19.80%) As of 05/2/2025 03:39 PM EasternIMAC Holdings, Inc. owns and manages innovative medical advancements and care regeneration centers, and backspace clinics in the United States. The company's outpatient medical clinics provide regenerative, orthopedic, and minimally invasive procedures and therapies to patients with sports injuries, ligament and tendon damage, and other related soft tissue conditions, as well as back, knee, and joint pains. It also provides medical treatments, regenerative, spinal decompression, chiropractic manipulation, and physical medicine and therapy. IMAC Holdings, Inc. was founded in 2000 and is headquartered in Franklin, Tennessee.Better Therapeutics NASDAQ:BTTX$0.0002 0.00 (0.00%) As of 05/2/2025 12:29 PM EasternBetter Therapeutics, Inc., a prescription digital therapeutics company, develops a form of cognitive behavioral therapy to address the causes of cardiometabolic diseases. The company's lead product candidate is BT-001, an investigational PDT platform to treat type 2 diabetes. It also develops software-based prescription digital therapeutics platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions. In addition, the company's clinical development candidates are intended to treat cardiometabolic diseases, including type 2 diabetes, hypertension, hyperlipidemia, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and chronic kidney disease. Its product pipeline also includes BT-002, which intends glycemic control for hypertension; BT-003 to reduce LDL cholesterol in patients with hyperlipidemia; and BT-004, which intends to explore the impact of treatment on liver health in patients with non-alcoholic steatohepatitis/non-alcoholic fatty liver disease. The company was founded in 2015 and is headquartered in San Francisco, California.UpHealth NYSE:UPHL$0.0002 0.00 (0.00%) As of 05/2/2025UpHealth, Inc. provides behavioral health solutions through the utilization of evidence-based treatments and services in the Americas. The company offers mental health and substance use disorder treatment services directly to consumers. It also provides detoxification, residential, partial hospitalization program, intensive outpatient program, outpatient services, and non-clinical recovery residence and supporting housing services. UpHealth, Inc. is headquartered in Delray Beach, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 04/28 - 05/02 Amazon Earnings: 2 Reasons to Love It, 1 Reason to Be Cautious Meta Takes A Bow With Q1 Earnings - Watch For Tariff Impact in Q2 Why Spotify Stock Still Has Room to Run in 2025 Is It Time to Load Up on Bond ETFs? Palantir Earnings: 1 Bullish Signal and 1 Area of Concern Roblox Stock Gains Momentum and Can Top $100 in 2025 Visa Q2 Earnings Top Forecasts, Adds $30B Buyback Plan Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
